Zenith Website Updated

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Zenith Website Updated

posted on Apr 26, 2016 11:03AM

Key sentence on home page "Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer."

New content on the Presentations and Publications page including the AACR poster and the Alberta Epigenetics Summit abstracts.

New content on the Programs pages for pipeline, oncology, prostate cancer, translational program and epigenetic priming.